Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study - Stojcheva, Nina; Gladman, Stacy; Soergel, Marianne; Zitt, Christof; Drake, Roxana; Lockett, Tony; Marchand, Carine; Fustier, Pierre; Stavropoulou, Vaia; Fernandez, Elena; Pettigiani, Nathana Lopes; Watkins, Kate; et al. (British journal of clinical pharmacology, 2023)
Keywords: antiviral; COVID‐19; DARPin; ensovibep; omicron; variants of concern; COVID-19; ensovibep; omicron; DARPin; variants of concern; antiviral